Skip to main content
Market Activity
CLOSE
Market Activity
Stocks
Funds + ETFs
Indexes
Commodities
Cryptocurrency
Currencies
Futures
Fixed Income
Global Markets
Quick Links
Real-Time Quotes
After-Hours Quotes
Pre-Market Quotes
Nasdaq-100
Symbol Screener
Online Brokers
Glossary
Sustainable Bond Network
Symbol Change History
IPO Performance
Ownership Search
Dividend History
Market Events
Economic Calendar
Earnings
IPO Calendar
Dividend Calendar
SPO Calendar
Analyst Activity
Analyst Recommendations
Daily Earnings Surprise
Forecast Changes
Commodities
Gold
Copper
Crude Oil
Natural Gas
Nasdaq Data
Statistical Milestones
Total Returns
Daily Market Statistics
See All Market Activity
News + Insights
CLOSE
Markets
Companies
Coronavirus
Technology
Personal Finance
Financial Advisors
Topics
Blockchain
Commodities
Cryptocurrencies
Earnings
Governance
IPOs
Retirement
Stocks
Features
World Reimagined
Smart Investing
Innovation Realized
Coronavirus Watch Newsletter
Cultural Capital
Market Makers by Phil Mackintosh
TotalMarkets Podcast
TradeTalks
Nasdaq Watch
See All News + Insights
Solutions
CLOSE
Raise & Access Capital
List with Nasdaq
Nasdaq Private Market Solutions
Investor Relations Intelligence
Optimize Governance Practices
Nasdaq Boardvantage Board Portal Software
Board Evaluations
Nasdaq Center for Board Excellence
ESG Reporting/Data Management
Corporate Services COVID-19 Center
Transform with Technology
Market Infrastructure Technology
Non-Traditional Exchanges & New Markets
Sell-Side Technology
Buy-Side Technology
Catastrophe Risk Technology
Gain Market Intelligence
Buy-Side Intelligence
Investment Data & Analytics
Market Data & Feeds
Nasdaq Global Indexes
Institutional Capital with eVestment
Trade Global Markets
Equities
Equity Derivatives
ETFs & ETPs
Fixed Income
Commodities
Connectivity
Post Trade Services
Clearing
Exchange Oversight
Sustainable Bonds
See All Solutions
About
CLOSE
Our People
Careers
Press Center
Contact
Quick Links
Diversity, Inclusion and Belonging
Nasdaq Marketsite
Investor Relations
ESG Reporting Guide
European Markets
Nasdaq Nordic Foundation
Nasdaq Thought Leadership
Nasdaq Initiatives
Nasdaq Responds to Covid-19
TotalMarkets
Public Policy Advocacy
Sustainability at Nasdaq
Nasdaq Entrepreneurial Center
Nasdaq Ventures
Nasdaq and the Cloud
See All About
Log in
Data is currently not available
Data is currently not available
Find a Symbol
Search for Press Releases
When autocomplete results are available use up and down arrows to review and enter to select. Touch device users, explore by touch or with swipe gestures.
Edit my quotes
vTv Therapeutics Inc. Class A Common Stock
(VTVT)
Nasdaq
Listed
Nasdaq
100
Data is currently not available
Add to Watchlist
Add to Portfolio
Quotes
Summary
Live
Real-Time
Live
After-Hours
Live
Pre-Market
Live
Charts
Live
NEWS & ANALYSIS
News
Live
Press Releases
Live
Analyst Research
Live
Dividend History
Historical Quotes
Historical NOCP
Financials
Earnings
P/E & PEG Ratios
Option Chain
Short Interest
Institutional Holdings
Insider Activity
SEC Filings
Revenue EPS
VTVT
VTVT PRESS RELEASES
VTVT Press Releases
Published
Jan 6, 2021
vTv Therapeutics to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event Virtually
Published
Jan 6, 2021
Published
Dec 15, 2020
vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer’s Disease and Type 2 Diabetes
Published
Dec 15, 2020
Published
Dec 15, 2020
Aditum Bio Announces Formation of Third Company, Anteris Bio
Published
Dec 15, 2020
Published
Dec 15, 2020
vTv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio
Published
Dec 15, 2020
Published
Nov 24, 2020
vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital
Published
Nov 24, 2020
Published
Nov 5, 2020
vTv Therapeutics Announces 2020 Third Quarter Financial Results and Update
Published
Nov 5, 2020
Published
Nov 4, 2020
vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST Study
Published
Nov 4, 2020
Published
Oct 29, 2020
vTv Therapeutics to Present Study Update and Preliminary Data on Baseline Characteristics of Study Participants in Phase 2 Elevage Study Evaluating Azeliragon at 13th Clinical Trials on Alzheimer’s Disease (CTAD) Digital Event
Published
Oct 29, 2020
Published
Sep 23, 2020
vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes
Published
Sep 23, 2020
Published
Sep 16, 2020
vTv Therapeutics to Present Additional Positive Clinical Study Results from Phase 2 Simplici-T1 Study of TTP399 as Adjunctive Therapy for Patients with Type 1 Diabetes at EASD Virtual Meeting
Published
Sep 16, 2020
Published
Sep 15, 2020
vTv Therapeutics Announces Appointment of Edward P. Taibi to its Board of Directors
Published
Sep 15, 2020
Published
Aug 3, 2020
vTv Therapeutics Announces 2020 Second Quarter Financial Results and Update
Published
Aug 3, 2020
Published
Jul 27, 2020
vTv Therapeutics to Present Additional Clinical Data from the STEADFAST Study of Azeliragon at the Virtual Alzheimer's Association International Conference
Published
Jul 27, 2020
Published
Jun 13, 2020
vTv Therapeutics Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at the American Diabetes Association’s Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes Patients
Published
Jun 13, 2020
Published
May 22, 2020
vTv Therapeutics Changes its 2020 Annual Meeting of Stockholders to Virtual Format
Published
May 22, 2020
Published
May 7, 2020
vTv Therapeutics Announces 2020 First Quarter Financial Results and Update
Published
May 7, 2020
Published
Feb 20, 2020
vTv Therapeutics Announces 2019 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Published
Feb 20, 2020
Published
Feb 10, 2020
vTv Therapeutics Announces Positive Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes
Published
Feb 10, 2020
Published
Feb 7, 2020
vTv Therapeutics to Host Investor Call and Announce Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 – Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes
Published
Feb 7, 2020
Published
Dec 2, 2019
vTv Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
Published
Dec 2, 2019
...
Back to VTVT Overview
Related Symbols
AMZN
Data is currently not available
AAPL
Data is currently not available
TSLA
Data is currently not available
INTC
Data is currently not available
My Quotes
My Quotes
Watchlist
Portfolio
Add/Edit Symbols
View as Table
Add symbols
now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing
stocks
,
funds and ETFs
, and
more asset classes.
/
Add to Watchlist
Edit Watchlist
Your Watchlist is empty.
Add a Symbol
Create your Watchlist to save your favorite quotes on Nasdaq.com.
Log in
or
create a free account
to get started.
/
Outsmart the market with Smart Portfolio analytical tools powered by TipRanks.
Go to Smart Portfolio
Back
Add a symbol to your watchlist
Most Active
Data is currently not available
Edit My Quotes
Add up to 25 symbols
Enter up to 25 symbols separated by spaces. These symbols will be available throughout the site during your session.
Save data
Data is currently not available
Your symbols have been updated
You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com.
Continue